Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

被引：0
|
作者：
Tavara, B. [1 ]
Garrido, M. L. [1 ]
Rodriguez, Z. [1 ]
Rojas, M. [1 ]
Lopez, L. [1 ]
Medina, S. [1 ]
Ponte, C. [1 ]
Lopez, A. [1 ]
Sanchez, E. [1 ]
Pedraza, M. [1 ]
Vinals, P. [1 ]
Lopez, M. [1 ]
Alonso, D. [1 ]
Rodriguez, A. [1 ]
Davila, E. [1 ]
Castanon, C. [1 ]
De Sande, L. M. [1 ]
Nieto, B. [1 ]
Vallejo Pascual, M. E. [2 ]
Rodriguez, J. D. L. R. [1 ]
Garcia Palomo, A. [1 ]
Diz Tain, P. [1 ]
机构：
[1] Complejo Asistencial Univ Leon, Leon, Spain
[2] Univ Leon, Leon, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
DURVALUMAB; PACIFIC; REAL WORLD DATA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP05.02-0
引用
收藏
页码：S283 / S283
页数：1
相关论文
共 50 条
  • [31] Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience
    Concepcion, J. Rivera
    Prodduturvar, P.
    Gao, R. W.
    Schwecke, A. J.
    Potter, A.
    Moffett, J. N.
    Hocum, C.
    Day, C. N.
    Harmsen, W.
    Dimou, A.
    Mansfield, A.
    Ernani, V.
    Molina, J.
    Adjei, A. A.
    Marks, R.
    Schild, S. E.
    Yu, N. Y.
    Savvides, P. S.
    Garces, Y. I.
    Merrell, K. W.
    Routman, D.
    Breen, W. G.
    Olivier, K. R.
    Sio, T. T.
    Bush, A.
    Hoppe, B. S.
    Ko, S.
    Amundson, A. C.
    Majeed, U.
    Lou, Y.
    Butts, E.
    Oliver, T.
    Owen, D.
    Leventakos, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S271 - S271
  • [32] Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer
    Harada, Daijiro
    Shimonishi, Atsushi
    Saeki, Kazuhiko
    Ninomiya, Takashi
    Kanzaki, Hiromitsu
    Nagasaki, Kei
    Ogura, China
    Tsutsui, Yoko
    Kojin, Kazuhiro
    Hamamoto, Yasushi
    Kozuki, Toshiyuki
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (02) : E111 - E117
  • [33] Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)
    Kikuchi, H.
    Mizugaki, H.
    Tsuji, K.
    Yokoo, K.
    Tsurumi, K.
    Sugisaka, J.
    Kimura, N.
    Yokouchi, H.
    Sumi, T.
    Kawai, Y.
    Kobashi, K.
    Morita, R.
    Ito, K.
    Kitamura, Y.
    Minemura, H.
    Nakamura, K.
    Tanaka, H.
    Takashina, T.
    Konno, S.
    Oizumi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1626 - S1627
  • [34] Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)
    Tsuji, Kosuke
    Mizugaki, Hidenori
    Yokoo, Keiki
    Kobayashi, Maki
    Kawashima, Yosuke
    Kimura, Nozomu
    Yokouchi, Hiroshi
    Kikuchi, Hajime
    Sumi, Toshiyuki
    Kawai, Yasutaka
    Kobashi, Kenta
    Morita, Ryo
    Ito, Kenichiro
    Kitamura, Yasuo
    Minemura, Hiroyuki
    Nakamura, Keiichi
    Aso, Mari
    Honjo, Osamu
    Tanaka, Hisashi
    Takashina, Taichi
    Tsurumi, Kyoji
    Sugisaka, Jun
    Tsukita, Yoko
    Konno, Satoshi
    Oizumi, Satoshi
    CANCER SCIENCE, 2024, 115 (04) : 1273 - 1282
  • [35] Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
    Katayama, H
    Ueoka, H
    Kiura, K
    Tabata, M
    Kozuki, T
    Tanimoto, M
    Fujiwara, T
    Tanaka, N
    Date, H
    Aoe, M
    Shimizu, N
    Takemoto, M
    Hiraki, Y
    BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 979 - 984
  • [36] Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
    H Katayama
    H Ueoka
    K Kiura
    M Tabata
    T Kozuki
    M Tanimoto
    T Fujiwara
    N Tanaka
    H Date
    M Aoe
    N Shimizu
    M Takemoto
    Y Hiraki
    British Journal of Cancer, 2004, 90 : 979 - 984
  • [37] Immunotherapy in advanced non-small-cell lung cancer (NSCLC) after progression on chemotherapy: real-world results from a prospective institutional cohort
    Batra, Ullas
    Chufal, Kundan Singh
    Nathany, Shrinidhi
    Ahmad, Irfan
    Chowdhary, Rahul Lal
    Sharma, Mansi
    Jain, Praveen
    Gairola, Munish
    IMMUNOTHERAPY, 2022, 14 (11) : 851 - 858
  • [38] Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer
    Kashihara, Tairo
    Nakayama, Yuko
    Okuma, Kae
    Takahashi, Ayaka
    Kaneda, Tomoya
    Katagiri, Mika
    Nakayama, Hiroki
    Kubo, Yuko
    Ito, Kimiteru
    Nakamura, Satoshi
    Takahashi, Kana
    Inaba, Koji
    Murakami, Naoya
    Saito, Tetsuo
    Okamoto, Hiroyuki
    Itami, Jun
    Kusumoto, Masahiko
    Ohe, Yuichiro
    Igaki, Hiroshi
    RADIOTHERAPY AND ONCOLOGY, 2023, 180
  • [39] A Real-World Molecular Epidemiological Study of Non-Small-Cell Lung Cancer (NSCLC) Patients from Western India
    Joshi, Ashish
    Korgavkar, Reshma
    Joshi, Kshitij
    Maniar, Vashishth
    Kalaskar, Pritam
    Kendre, Pradip
    Maheshwari, Udip Dilip
    Pethe, Chandrashekhar
    Sheth, Smith
    Dhande, Sonal
    SOUTH ASIAN JOURNAL OF CANCER, 2023, 12 (03) : 263 - 265
  • [40] Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States
    Lin, Huamao M.
    Wu, Yanyu
    Yin, Yu
    Niu, Huifeng
    Curran, Eileen A.
    Lovly, Christine M.
    Humphries, Michael J.
    CLINICAL LUNG CANCER, 2023, 24 (01) : E39 - E49
12345